Your browser doesn't support javascript.
loading
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies: JACC: CardioOncology State-of-the-Art Review.
Leong, Darryl P; Cirne, Filipe; Aghel, Nazanin; Baro Vila, Rocio C; Cavalli, Germano D; Ellis, Peter M; Healey, Jeff S; Whitlock, Richard; Khalaf, Dina; Mian, Hira; Jolly, Sanjit S; Mehta, Shamir R; Dent, Susan.
Afiliación
  • Leong DP; The Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Cirne F; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Aghel N; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Baro Vila RC; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Cavalli GD; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Ellis PM; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Healey JS; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
  • Whitlock R; The Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Khalaf D; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Mian H; The Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Jolly SS; Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
  • Mehta SR; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
  • Dent S; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
JACC CardioOncol ; 5(4): 415-430, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37614581
ABSTRACT
Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: JACC CardioOncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: JACC CardioOncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá